← back to search

John G. Kuhn

University of California, Los Angeles · US
Area of research
Genetics · Oncology
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, and Lung Cancer Treatments and Mutations.
h-index
64
citations
12,357
works
303
NIH funding
primary concept
email

Recent publications

Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
Clinical Cancer Research 2022cited by 56position: middledoi
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
Science Translational Medicine 2021cited by 107position: middledoi
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Journal of Clinical Oncology 2019cited by 153position: middledoi
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: A report from the Pacific Pediatric Neuro‐Oncology Consortium
International Journal of Cancer 2019cited by 132position: middledoi
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Breast Cancer Research 2019cited by 67position: middledoi
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Clinical Cancer Research 2017cited by 81position: middledoi
Toward precision medicine in glioblastoma: the promise and the challenges
Neuro-Oncology 2015cited by 222position: middledoi
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Neuro-Oncology 2014cited by 166position: middledoi
Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Cancer Discovery 2012cited by 342position: middledoi
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Neuro-Oncology 2012cited by 110position: middledoi

Grants

I-Corps: Scalable conversion of carbon dioxide to value-added commodity chemicals
NSF1743623$50,0002017–2019PIRePORTER
A PLASMON-ENHANCED TEMPERATURE-SWING PROCESS FOR CONVERSION OF CARBON DIOXIDE TO CARBON MONOXIDE
NSF1335817$325,9052013–2017PIRePORTER

Frequent collaborators

Timothy F. Cloughesy · UCLA Medical Center3 papers (2012–2015)Mary R. Schwartz · Houston Methodist2 papers (2019–2021)Angel Rodriguez · Signature Research (United States)2 papers (2019–2021)Jorge Darcourt · Methodist Hospital2 papers (2019–2021)Wei Qian · Chinese Academy of Sciences2 papers (2019–2021)W.K. Alfred Yung · The University of Texas MD Anderson Cancer Center2 papers (2012–2014)Anna Belcheva · Houston Methodist2 papers (2019–2021)Keith L. Ligon · Harvard University2 papers (2014–2015)Frank S. Lieberman · University of Pittsburgh2 papers (2012–2014)Janet Dancey · Queen's University2 papers (2012–2014)Patrick Y. Wen · Harvard University2 papers (2014–2015)Jenny C. Chang · Houston Methodist2 papers (2019–2021)Minesh P. Mehta · Carbon Engineering (Canada)2 papers (2012–2014)Michael D. Prados · University of San Francisco2 papers (2012–2015)H. I. Robins · Adaptive Biotechnologies (United States)2 papers (2012–2014)Kathleen R. Lamborn · Neurological Surgery2 papers (2012–2014)Eric Bernicker · Methodist Hospital1 papers (2021–2021)John D. Carpten · City Of Hope National Medical Center1 papers (2015–2015)Jane Meisel · Emory University1 papers (2019–2019)Lauren E. Abrey · Roche (Switzerland)1 papers (2012–2012)